Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes relapse: medium term (13‐25 weeks) as defined in each study compared with PLACEBO (very low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
1 finding from 1 review
Global state Global Assessment Scale (GAS) · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: medium term (13‐25 weeks) as defined in each study · patients with schizophrenia
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes leaving the study early/ loss to compared with PLACEBO (very low certainty).
1 finding from 1 review
Weight gain · people with psychosis
1 finding from 1 review
Weight gain (equal or greater then 7% of baseline) · people with psychosis
1 finding from 1 review
High prolactin at any time during treatment · people with psychosis
1 finding from 1 review
Change in corrected QT · people with psychosis
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Hospital admissions · patients with schizophrenia
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Weight gain · patients with schizophrenia
Bromperidol decanoate showed no clear difference in adverse effects ‐ increased weight compared with placebo (low certainty).
1 finding from 1 review
Adverse effects ‐ stiffness · patients with schizophrenia
Bromperidol decanoate showed no clear difference in adverse effects ‐ stiffness compared with placebo (low certainty).
1 finding from 1 review
Sexual function: Subjective assessment (number of erections) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found